open access

Vol 68, No 2 (2017)
REVIEWS — Postgraduate Education
Published online: 2017-05-08
Submitted: 2017-04-04
Accepted: 2017-04-05
Get Citation

Gastroduodenal neuroendocrine neoplasms, including gastrinoma — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Michał Lipiński, Grażyna Rydzewska, Wanda Foltyn, Elżbieta Andrysiak-Mamos, Agata Bałdys-Waligórska, Tomasz Bednarczuk, Jolanta Blicharz-Dorniak, Marek Bolanowski, Agnieszka Boratyn-Nowicka, Małgorzata Borowska, Andrzej Cichocki, Jarosław B. Ćwikła, Massimo Falconi, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Barbara Jarząb, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kamiński, Agnieszka Kolasińska-Ćwikła, Aldona Kowalska, Robert Król, Leszek Królicki, Jolanta Kunikowska, Katarzyna Kuśnierz, Paweł Lampe, Dariusz Lange, Anna Lewczuk-Myślicka, Andrzej Lewiński, Magdalena Londzin-Olesik, Bogdan Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Joanna Pilch-Kowalczyk, Karolina Poczkaj, Violetta Rosiek, Marek Ruchała, Lucyna Siemińska, Anna Sowa-Staszczak, Teresa Starzyńska, Katarzyna Steinhof-Radwańska, Janusz Strzelczyk, Krzysztof Sworczak, Anhelli Syrenicz, Andrzej Szawłowski, Marek Szczepkowski, Ewa Wachuła, Wojciech Zajęcki, Anna Zemczak, Wojciech Zgliczyński, Beata Kos-Kudła
DOI: 10.5603/EP.2017.0016
·
Pubmed: 28540972
·
Endokrynologia Polska 2017;68(2):138-153.

open access

Vol 68, No 2 (2017)
REVIEWS — Postgraduate Education
Published online: 2017-05-08
Submitted: 2017-04-04
Accepted: 2017-04-05

Abstract

This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neuroendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, pathogenesis, and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological, and localisation diagnoses. The principles of treatment are discussed, including endoscopic, surgical, pharmacological, and radionuclide treatments. Finally, there are also recommendations on patient monitoring.

Abstract

This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neuroendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, pathogenesis, and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological, and localisation diagnoses. The principles of treatment are discussed, including endoscopic, surgical, pharmacological, and radionuclide treatments. Finally, there are also recommendations on patient monitoring.

Get Citation

Keywords

neuroendocrine neoplasms; stomach; duodenum; gastrinoma; diagnostics; therapy; guidelines

About this article
Title

Gastroduodenal neuroendocrine neoplasms, including gastrinoma — management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Journal

Endokrynologia Polska

Issue

Vol 68, No 2 (2017)

Pages

138-153

Published online

2017-05-08

DOI

10.5603/EP.2017.0016

Pubmed

28540972

Bibliographic record

Endokrynologia Polska 2017;68(2):138-153.

Keywords

neuroendocrine neoplasms
stomach
duodenum
gastrinoma
diagnostics
therapy
guidelines

Authors

Michał Lipiński
Grażyna Rydzewska
Wanda Foltyn
Elżbieta Andrysiak-Mamos
Agata Bałdys-Waligórska
Tomasz Bednarczuk
Jolanta Blicharz-Dorniak
Marek Bolanowski
Agnieszka Boratyn-Nowicka
Małgorzata Borowska
Andrzej Cichocki
Jarosław B. Ćwikła
Massimo Falconi
Daria Handkiewicz-Junak
Alicja Hubalewska-Dydejczyk
Barbara Jarząb
Roman Junik
Dariusz Kajdaniuk
Grzegorz Kamiński
Agnieszka Kolasińska-Ćwikła
Aldona Kowalska
Robert Król
Leszek Królicki
Jolanta Kunikowska
Katarzyna Kuśnierz
Paweł Lampe
Dariusz Lange
Anna Lewczuk-Myślicka
Andrzej Lewiński
Magdalena Londzin-Olesik
Bogdan Marek
Anna Nasierowska-Guttmejer
Ewa Nowakowska-Duława
Joanna Pilch-Kowalczyk
Karolina Poczkaj
Violetta Rosiek
Marek Ruchała
Lucyna Siemińska
Anna Sowa-Staszczak
Teresa Starzyńska
Katarzyna Steinhof-Radwańska
Janusz Strzelczyk
Krzysztof Sworczak
Anhelli Syrenicz
Andrzej Szawłowski
Marek Szczepkowski
Ewa Wachuła
Wojciech Zajęcki
Anna Zemczak
Wojciech Zgliczyński
Beata Kos-Kudła

References (87)
  1. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010; 17(4): 909–918.
  2. O'Connor JM, Marmissolle F, Bestani C, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol. 2014; 2(5): 673–684.
  3. Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015; 121(4): 589–597.
  4. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–3072.
  5. O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26(6): 719–735.
  6. Delle Fave G, O'Toole D, Sundin A, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016; 103(2): 119–124.
  7. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metabol 2007; 21: 15–31.
  8. Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011; 33(12): 1361–1369.
  9. Borch K, Ahrén Bo, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005; 242(1): 64–73.
  10. Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012; 95(3): 207–213.
  11. WHO Classification of Tumours of the Digestive System. IARC: 2017 (in press)
  12. Plöckinger U. Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1). Cancers 2012; 4: 39–54.
  13. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012; 95(2): 74–87.
  14. Jensen RT, Rindi G, Arnold R, et al. Frascati Consensus Conference, European Neuroendocrine Tumor Society. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology. 2006; 84(3): 165–172.
  15. Lee KJ, Cho JH, Lee SH, et al. Clinicopathological characteristics of biliary neuroendocrine neoplasms: a multicenter study. Scand J Gastroenterol. 2017; 52(4): 437–441.
  16. Dumitrascu T, Dima S, Herlea V, et al. Neuroendocrine tumours of the ampulla of Vater: clinico-pathological features, surgical approach and assessment of prognosis. Langenbecks Arch Surg. 2012; 397(6): 933–943.
  17. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008; 15(1): 229–241.
  18. Ruszniewski P, Delle Fave G, Cadiot G, et al. Frascati Consensus Conference, European neuroendocrine Tumor Society. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006; 84(3): 158–164.
  19. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg. 2009; 46(1): 13–106.
  20. Jensen RT, Niederle B, Mitry E, et al. Frascati Consensus Conference, European Neuroendocrine Tumor Society. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006; 84(3): 173–182.
  21. Wilson SD, Doffek KM, Krzywda EA, et al. Zollinger-Ellison syndrome associated with a history of alcohol abuse: coincidence or consequence? Surgery. 2011; 150(6): 1129–1135.
  22. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006; 12(34): 5440–5446.
  23. Thakker RV, Newey PJ, Walls GV, et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9): 2990–3011.
  24. Harper S, Carroll RW, Frilling A, et al. Primary lymph node gastrinoma: 2 cases and a review of the literature. J Gastrointest Surg. 2015; 19(4): 651–655.
  25. Lu X, Aoun E, Morrissey S. Primary hepatic gastrinoma presenting as vague gastrointestinal symptoms. BMJ Case Rep. 2012; 2012.
  26. Naoe H, Iwasaki H, Kawasaki T, et al. Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. Case Rep Gastroenterol. 2012; 6(3): 590–595.
  27. Ogawa S, Wada M, Fukushima M, et al. Case of primary hepatic gastrinoma: Diagnostic usefulness of the selective arterial calcium injection test. Hepatol Res. 2015; 45(7): 823–826.
  28. Tonelli F, Giudici F, Nesi G, et al. Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. World J Gastroenterol. 2013; 19(45): 8312–8320.
  29. Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61(1): 6–32.
  30. Jensen RT, Cadiot G, Brandi ML, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012; 95(2): 98–119.
  31. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005; 19(5): 675–697.
  32. Kos-Kudła B, Blicharz-Dorniak J, Handkiewicz-Junak D, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 418–443.
  33. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007; 21(1): 33–41.
  34. Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008; 159(4): 475–482.
  35. Rehfeld JF, Federspiel B, Bardram L. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med. 2013; 368(12): 1165–1166.
  36. Woltering EA, Bergsland EK, Beyer DT, et al. American Joint Committee on Cancer 2017 M. B. Amin (eds. ) AJCC Cancer Staging Manual, Eight Edition. : 351–359.
  37. Brierley JD, Gospodarowicz MK, Wittekind C, et al. eds) UICC TNM Classification of Malignant Tumours. Eight Edition. Wiley Blackwell. ; 2017: 99–101.
  38. Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009; 16(11): 3154–3160.
  39. Rydzewska G, Cichocki A, Ćwikła JB, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 444–458.
  40. Scherübl H, Cadiot G, Jensen RT, et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010; 42(8): 664–671.
  41. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008; 40(8): 650–658.
  42. Zimmer T, Ziegler K, Liehr RM, et al. Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas. Ann N Y Acad Sci. 1994; 733: 425–436.
  43. Pilch-Kowalczyk J, Leszczyński S. Układ trawienny. W: Diagnostyka obrazowa. Układ trawienny (red.). Leszczyński S, Pilch-Kowalczyk J. PZWL, Warszawa 2012.
  44. Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumours. Digestion. 2000; 62 Suppl 1: 39–44.
  45. Flechsig P, Zechmann CM, Schreiweis J, et al. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. Eur J Radiol. 2015; 84(8): 1593–1600.
  46. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 40(5): 800–816.
  47. Wilcox CM, Seay T, Arcury JT, et al. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis. 2011; 43(6): 439–443.
  48. Yoshikane H, Suzuki T, Yoshioka N, et al. Duodenal carcinoid tumor: endosonographic imaging and endoscopic resection. Am J Gastroenterol. 1995; 90(4): 642–644.
  49. Zimmer T, Stölzel U, Bäder M, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996; 39(4): 562–568.
  50. Khan RN, Bansal VK, Kumar S, et al. Duodenal gastrinoma: a diagnostic dilemma. Am J Surg. 2009; 197(5): e48–e50.
  51. Acs G, McGrath CM, Gupta PK. Duodenal carcinoid tumor: report of a case diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy with immunocytochemical correlation. Diagn Cytopathol. 2000; 23(3): 183–186.
  52. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013; 168(2): 185–193.
  53. Kim HH, Kim GHa, Kim JiH, et al. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract. 2014; 2014: 253860.
  54. Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol. 2014; 109(2): 71–74.
  55. Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013; 19(46): 8687–8695.
  56. Chen WF, Zhou PH, Li QL, et al. Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. ScientificWorldJournal. 2012; 2012: 869769.
  57. Kwon YH, Jeon SW, Kim GHa, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol. 2013; 19(46): 8703–8708.
  58. Basford P, Bhandari P. Endoscopic resection of sporadic duodenal neuroendocrine tumors: Why is this not so easy? Endoscopy. 2016; 48(11): 965–966.
  59. Gincul R, Ponchon T, Napoleon B, et al. Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. Endoscopy. 2016; 48(11): 979–986.
  60. Hartel M, Wente MN, Sido B, et al. Carcinoid of the ampulla of Vater. J Gastroenterol Hepatol. 2005; 20(5): 676–681.
  61. Soga J. Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J Exp Clin Cancer Res. 2003; 22(3): 349–363.
  62. Jianu CS, Fossmark R, Syversen U, et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011; 46(4): 456–463.
  63. Fossmark R, Sørdal Ø, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012; 36(11-12): 1067–1075.
  64. Moore AR, Boyce M, Steele IA, et al. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013; 8(10): e76462.
  65. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000; 118(4): 696–704.
  66. Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009; 10(7): 1145–1157.
  67. Ojeaburu JV, Ito T, Crafa P, et al. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci. 2011; 56(1): 139–154.
  68. Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012; 10(2): 199–202.
  69. Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006; 7(2): 169–175.
  70. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015; 41(11): 1162–1174.
  71. Yadlapati R, Kahrilas PJ, Aronson JK, et al. SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1): 179.
  72. Schnoll-Sussman F, Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Curr Treat Options Gastroenterol. 2017; 15(1): 1–9.
  73. Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Lancet 2016;5. ; 387(10022): 968–77.
  74. NCCN Guidelines v 2.2016
  75. Krzakowski M, et al. Onkologia Kliniczna, Nowotwory układu wydzielania wewnętrznego. 2015: 789–836.
  76. Paganelli G, Bodei L, Handkiewicz Junak D, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2002; 66(6): 393–398.
  77. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010; 21(4): 787–794.
  78. Garcia-Carbonero R, Sorbye H, Baudin E, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016; 103(2): 186–194.
  79. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12): 2754–2762.
  80. Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38(12): 2125–2135.
  81. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17): 2416–2423.
  82. Sowa-Staszczak A, Pach D, Kunikowska J, et al. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours. Endokrynol Pol. 2011; 62(5): 392–400.
  83. Pach D, Sowa-Staszczak A, Kunikowska J, et al. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol. 2012; 102(1): 45–50.
  84. Kunikowska J, Królicki L, Sowa-Staszczak A, et al. Polish experience in Peptide receptor radionuclide therapy. Recent Results Cancer Res. 2013; 194: 467–478.
  85. Vinjamuri S, Gilbert TM, Banks M, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013; 108(7): 1440–1448.
  86. Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135.
  87. OCEBM Levels of Evidence Working Group*. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ index.aspx?o=5653.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl